Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut, discusses a poster presentation comparing the itch relief data of upadacitinib (Rinvoq) vs dupilumab (Dupixent) in adults and adolescents with moderate-to-severe atopic dermatitis. The results of the phase 3/b4 Level Up study (NCT05601882) presented at the 2026 Winter Clinical Dermatology Conference in Hawaii showed a higher proportion of patients who received upadacitinib achieved clinically meaningful reduction itch by the beginning of Day 2 compared to dupilumab. Dr. Bunick says this trend was seen continuously throughout the study. By Day 28, more than half (50.8%) of patients treated with upadacitinib achieved clinically meaningful itch improvement. Comparatively, 29.3% of patients treated with dupilumab achieved clinically meaningful itch improvement by Day 28.
